patents of Lovaza will start expiring as early as March 2013, Vascepa NCE takes control..
The patents of Lovaza will start expiring as early as March 2013, giving way to cheaper generics. The decision to commercialize Vascepa seems to be a strategic move by Zakrzewski. Investors should remember that prior to the sale of Reliant to GSK, the company had already commercialized Lovaza. Therefore, investor perception that Amarin is no longer an acquisition target is totally misplaced.